Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DFP Healthcare Acquisitions Corp. is a blank check company. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying a target business in the healthcare or healthcare-related industries in the United States and other developed countries. The Company focuses its investment effort across the entire healthcare industry, which encompasses services, therapeutics, devices, diagnostics and animal health.Oncology Institute, Inc. (TOI) shareholder M33 Growth I LP filed Amendment No. 5 to its Schedule 13D to update its ownership in the company’s common stock.
The reporting persons now beneficially own 6,802,656 shares of TOI common stock, including 5,444,207 shares held by M33 Growth I LP and 1,358,449 shares issuable upon exercise of warrants with a $1.1980 per share exercise price. This represents 5.46% of TOI’s common stock, based on 98,381,340 shares outstanding as of November 6, 2025 plus the warrant shares.
On November 18, 2025, M33 Growth I LP distributed 2,488,182 shares of common stock in-kind to its limited partners, and TOI M, LLC distributed 590,892 shares in-kind to its members. Following these distributions, TOI M, LLC no longer beneficially owns any TOI common stock, while M33 Growth I LP and its general partner M33 Growth I GP LLC continue to report shared voting and dispositive power over 6,802,656 shares.
The Oncology Institute, Inc. (TOI) reported that its Chief Executive Officer acquired additional common stock through a stock-based award. On 11/17/2025, the officer received 6,464 shares of common stock at a stated price of $0.00 per share, increasing their directly held stake to 1,799,984 shares.
The filing explains that these 6,464 shares represent restricted stock units (RSUs) that were fully vested upon grant, after shares were withheld to cover tax obligations. This is a routine equity compensation event that aligns the CEO’s interests more closely with those of other shareholders.
Oncology Institute, Inc. (TOI) reported an insider equity transaction by a person serving as Chief Medical Officer on a Form 4. On 11/17/2025, this reporting person acquired 2,086 shares of common stock at $0.00 per share. These shares represent restricted stock units that were fully vested upon grant and delivered net of withholding tax obligations.
After this transaction, the reporting person directly beneficially owns 237,930 shares of Oncology Institute common stock.
Oncology Institute, Inc. (TOI) reported an equity award to its Chief Financial Officer, who is an officer and reporting person of the company. On 11/17/2025, the CFO acquired 195 shares of common stock as restricted stock units (RSUs) that were fully vested upon grant, with no cash price shown for the shares. After this transaction, the officer beneficially owned 235,369 shares of TOI common stock in direct ownership. The RSUs were net of shares withheld to cover tax obligations.
A shareholder filed a Form 144 notice to sell up to 50,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $200,000. The shares relate to restricted stock acquired from the issuer in several grants between November 17, 2022 and June 14, 2024. The planned sale is listed for approximately November 18, 2025 on the NASDAQ, where about 98,381,340 shares of this class are outstanding. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations and acknowledges that intentional misstatements can constitute a federal criminal violation.
Oncology Institute (TOI) Chief Executive Officer Daniel Virnich reported an insider equity award. The Form 4 shows 6,211 shares of common stock acquired at $0.00 on 11/12/2025, reflecting RSUs that were fully vested upon grant and settled net of withholding taxes. Following this transaction, he beneficially owned 1,793,520 shares, held directly.
Oncology Institute, Inc. (TOI) insider activity: A Form 4 reports that the company’s Chief Medical Officer acquired common stock via restricted stock units (RSUs) that were fully vested upon grant on 11/12/2025.
The filing lists two RSU-related acquisitions at a price of $0.00 per share: 306 shares and 1,202 shares, reported as net of withholding tax obligations. Following these transactions, the reporting person beneficially owned 235,844 shares.
The Oncology Institute, Inc. (TOI) furnished an investor presentation under Item 7.01 (Regulation FD) via an 8-K. The presentation, dated November 14, 2025, is attached as Exhibit 99.1. TOI states this information is furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act or Exchange Act filings. TOI’s securities trade on Nasdaq under TOI (common stock) and TOIIW (redeemable warrants).
The Oncology Institute, Inc. (TOI) reported Q3 2025 results with total operating revenue of $136.6 million, up from $99.9 million a year ago, driven mainly by dispensary sales. Dispensary revenue reached $75.9 million versus $48.2 million, while patient services were $60.2 million versus $49.8 million. Capitated revenue was $20.6 million versus $14.8 million.
The company posted a Q3 loss from operations of $8.1 million, improving from a $13.9 million loss, and a net loss of $16.5 million. Year‑to‑date revenue was $360.8 million with a net loss of $53.1 million. Cash and cash equivalents were $27.7 million at quarter‑end, and net cash used in operations was $27.8 million for the nine months.
TOI reduced SG&A and executed financing actions: a $20.0 million partial prepayment of its Senior Secured Convertible Notes and removal of the $40.0 million minimum cash covenant; approximately $16.5 million in gross proceeds from a private placement; and $11.8 million in aggregate gross proceeds under its at‑the‑market program, including 3.4 million shares sold in Q3. Long‑term debt was $76.2 million, and stockholders’ equity was a deficit of $12.3 million. Management concluded it has sufficient liquidity for at least one year.
The Oncology Institute, Inc. filed a current report stating that it issued a press release announcing its financial results for the three months ended September 30, 2025.
The company furnished the press release as Exhibit 99.1, which includes details about its results of operations and financial condition for the quarter, along with other financial information. The company notes that this information is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.